As per NPPA Order S.O. 5690(E) dated 17 October 2026, the trade margin on 137 non-scheduled anti-cancer medicines is capped at 30%. Hetero’s revised MRPs take effect on 9 November 2026.
Patients and partners with questions about the revised prices are welcome to speak to their doctor, pharmacist or hospital.
Source: NPPA Order S.O. 5690(E), The Gazette of India, 17 October 2026.
The BLISS Division of Hetero Healthcare is focused on providing therapeutic solutions across gastrointestinal and digestive health, addressing a broad spectrum of conditions that affect the stomach, intestines, and overall digestive well-being. The division aims to support healthcare professionals with effective treatment options for commonly encountered gastrointestinal concerns as well as conditions requiring continued clinical management.
Its therapeutic portfolio addresses areas such as acidity and acid-related disorders, gastroesophageal reflux, digestive disturbances, nausea and vomiting, constipation, and other gastrointestinal conditions. Through a combination of targeted and supportive therapies, BLISS strives to facilitate comprehensive digestive care and help improve patients’ comfort and quality of life.
Backed by Hetero Healthcare’s commitment to quality, accessibility, and patient-centric healthcare, the BLISS Division continues to strengthen its presence in gastrointestinal care. With a focused approach to evolving digestive healthcare needs, the division aims to support effective clinical management and contribute to better treatment experiences and patient outcomes.
View by-
